The Latest Breaking News from Bayer AG

On Wednesday, Bayer AG (OTC:BAYRY) reported adjusted earnings of 17 cents per ADS (57 cents in euros), up from 7 cents a year ago (24 cents euros).

The Duplomb Law is being fiercely contested by civil society and a petition opposes the reintroduction of a pesticide.

Bayer AG and Regeneron Pharmaceuticals Inc.’s blockbuster eye drug reached another clinical milestone by showing sustained efficacy in trials that could help the companies push back against a competing product from Roche Holding AG.

With job growth remaining strong in June, the Fed is expected to raise interest rates aggressively. Therefore, the stock market may witness further downside. Amid this backdrop, it could be wise to invest in large-cap stocks Bristol-Myers Squibb (BMY), Bayer (BAYRY), and Mitsubishi Heavy Industries (MHVYF), which have shown resilience…

Inelastic demand, growing investments, and impressive breakthroughs should help the healthcare sector survive the potential recession. This is why we believe quality healthcare stocks Assertio (ASRT), Bayer (BAYRY), Bristol-Myers Squibb (BMY), Catalyst Pharmaceuticals (CPRX), and Ipsen (IPSEY), which are currently trading at discounts to their peers, could be solid investments…

BWX Technologies Inc (NYSE:BWXT) subsidiary BWXT Medical Ltd. has entered a commercial agreement with Bayer AG (OTC:BAYRY) to supply high-purity Actinium-225 (Ac-225). Bayer will purchase high-purity Ac-225 from BWXT Medical at pre-determined prices. The parties expect supply to commence later this year. The above agreement follows the agreement reached by the parties in September 2021.…

Late last week, Atara Biotherapeutics Inc (NASDAQ:ATRA) announced that Bayer AG (OTC:BAYRY) intends to terminate the exclusive worldwide licensing agreement for Atara's mesothelin-targeted allogeneic and autologous CAR-T assets, ATA3271 and ATA2271. The enrollment was paused in the Phase 1 trial of ATA2271 for mesothelioma after a patient death. The move followed a strategic review and asset-level prioritization.…

Atara Biotherapeutics Inc (NASDAQ:ATRA) received notification that Bayer AG's (OTC:BAYRY) intends to end the exclusive worldwide licensing agreement for mesothelin-directed CAR T-cell therapies. The collaboration included the funding and development of ATA3271, allogeneic T-cell immunotherapy, and an autologous version, ATA2271, for high mesothelin-expressing tumors.  ATA3271 leverages Atara's EBV T-cell platform and is currently in IND…

Bayer AG (OTC: BAYRY) has